Shopping Cart
Remove All
Your shopping cart is currently empty
C105SR is a cyclophilin D (CypD) inhibitor targeting peptidyl-prolyl cis-trans isomerase (PPIase). It has an IC50 value of 5 nM for inhibiting mitochondrial permeability transition pore (mPTP) opening. C105SR reduces apoptosis in hepatocytes induced by hypoxia-reoxygenation and boosts calcium retention capacity (CRC). It demonstrates hepatoprotective effects in a mouse model of ischemia-reperfusion injury (IRI).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | C105SR is a cyclophilin D (CypD) inhibitor targeting peptidyl-prolyl cis-trans isomerase (PPIase). It has an IC50 value of 5 nM for inhibiting mitochondrial permeability transition pore (mPTP) opening. C105SR reduces apoptosis in hepatocytes induced by hypoxia-reoxygenation and boosts calcium retention capacity (CRC). It demonstrates hepatoprotective effects in a mouse model of ischemia-reperfusion injury (IRI). |
| In vitro | C105SR at varying concentrations (0.5/1/5/10/50/100 μM) inhibits mitochondrial CypD PPIase activity. Additionally, C105SR at 1 μM for 4 hours under hypoxia (1% O2) followed by 1 hour of reoxygenation (21% O2) prevents mPTP opening. Furthermore, C105SR (0.5/1/5/10/50/100 μM) administered for 4 hours during hypoxia (1% O2) reduces hypoxia/reoxygenation-induced death in AML-12 cells. |
| In vivo | C105SR (50 mg/kg, administered subcutaneously, 24 hours prior to ischaemia–reperfusion injury (IRI) surgery, single dose) demonstrates a protective effect in a mouse model of hepatic ischaemia–reperfusion injury.' |
| Molecular Weight | 633.60 |
| Formula | C32H33BrN4O3S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.